Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRACAN: Atezolizumab and Tiragolumab in Solid Tumors
NCT05483400Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in head and neck squamous cell carcinoma (HNSCC), microsatellite instability-high cancer, melanoma, solid tumor, sponsored by University Medical Center Groningen. Started Oct 2023; status: recruiting.
02
Drugs
tiragolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)microsatellite instability-high cancermelanomasolid tumor
Beyond the preview
Go deeper on NCT05483400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483400.